Navigation Links
Nonmedical treatment may rapidly relieve severe IBS symptoms
Date:4/27/2010

A significant proportion of irritable bowel syndrome (IBS) patients treated with cognitive behavior therapy have a positive response within four weeks of treatment, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.

"Patients who quickly achieve treatment gains for example, IBS symptom relief may be spared the cost and inconvenience of follow-up care of little therapeutic value. This scenario may lead to the development of self-guided treatments based on multimedia technology, such as Web, DVD and smartphone, and free up trained clinicians to focus on more severely affected patients," said Jeffrey M. Lackner, PsyD, of the University at Buffalo, SUNY, and lead author of the study. "Conversely, patients who do not respond within a set number of sessions early on could be immediately identified and triaged or 'stepped up' to potentially more powerful treatment(s) rather than bearing the cost, demoralization and frustration that comes with treatment failure."

In a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases, doctors investigated whether patients who achieved rapid, substantial and sustained symptom improvements relatively early in treatment (by week four) called "rapid responders" maintain treatment gains, compared with non-rapid responders. A total of 71 patients were randomly assigned to undergo 10 weekly, one-hour sessions of cognitive behavior therapy or four, one-hour cognitive behavior therapy sessions over 10 weeks. Rapid responders were classified as patients who reported adequate relief of pain, adequate relief of bowel symptoms and a decrease in total IBS severity scores of greater than or equal to 50 by week four.

Of patients undergoing cognitive behavior therapy, 30 percent were rapid responders, of whom 90 percent to 95 percent maintained gains at the immediate and three-month follow-up examinations. Although the rapid responders reported more severe IBS symptoms at baseline, they achieved more substantial, sustained IBS symptom reduction than non-rapid responders. Both dosages of cognitive behavior therapy had comparable rates of rapid responders.

"We don't believe the rapidity of response is simply because rapid responders had less severe IBS when they began treatment. In fact, rapid responders had more severe IBS symptoms and quality of life impairment than other patients. Nor did we find evidence to support the notion that patients responded more rapidly just because they were less distressed," added Dr. Lackner. "Further research is needed to clarify whether rapid responders maintain treatment response longer term and, if so, what drives the durability of treatment response."

The great majority of rapid responders (92 percent) showed lasting benefit that persisted three months after treatment ended with no evidence of deterioration. This suggests that rapid response is a relatively robust, clinically meaningful and enduring clinical phenomenon. In fact, rapid responders maintained or continued to improve on the gains made in treatment.


'/>"/>

Contact: Alissa J. Cruz
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. Steroids May Be Overrated in Treatment of COPD
2. Experimental stem cell treatment arrests acute lung injury in mice, study shows
3. Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
4. New study shows effectiveness of MEND program in prevention and treatment of pediatric obesity
5. New York City Surgeon Develops All-Natural Treatment for Wrinkles and Scars
6. Novelty lures rats from cocaine-paired settings, hinting at new treatments for recovering addicts
7. Northeast Chiropractic, PC Revolutionizes Pain Management Without Medication, Now Offering New and Unique Blend of Treatments
8. Autism-Supplements.com and Generation Rescue Work Together to Raise Money for Biomedical Autism Treatments
9. Biomarker could help doctors tailor treatment for rheumatoid arthritis
10. St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh
11. Jefferson neurosurgeon helps draft new treatment guidelines for brain metastases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology: